Abstract
Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in ∼40–50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- Ad:
-
adenovirus
- APC:
-
allophycocyanine
- AS:
-
antisense
- CAR:
-
Coxsackievirus and adenovirus receptor
- ECL:
-
enhanced chemiluminescence
- ERK:
-
extracellular signal-regulated kinase
- FACS:
-
fluorescent-activated cell sorting
- FITC:
-
fluorescein isothiocyanate
- gapdh :
-
glyceraldehyde-3-phosphate dehydrogenase
- GFP:
-
green fluorescent protein
- IFN-β:
-
beta (fibroblast) interferon
- IL:
-
interleukin
- MAPK:
-
mitogen-activated protein kinase
- mda-7:
-
melanoma differentiation associated gene-7
- MEK:
-
MAPK/ERK kinase
- MEZ:
-
mezerein
- m.o.i.:
-
multiplicity of infection
- MTT:
-
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- pfu:
-
plaque-forming units
- PI:
-
propidium iodide
- PKC:
-
protein kinase C
- scAb:
-
single-chain antibody
References
Adjei AA . (2001). Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93: 1062–1074.
Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ et al. (2001). Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85: 692–696.
Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M . (1997). Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinogen 20: 251–258.
Barbacid M . (1987). ras genes. Annu Rev Biochem 56: 779–827.
Bos JL . (1989). ras oncogenes in human cancer: a review. Cancer Res 49: 4682–4689.
Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ et al. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297.
Brand K, Klocke R, Possling A, Paul D, Strauss M . (1999). Induction of apoptosis and G2/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection. Gene Therapy 6: 1054–1063.
Canevari S, Biocca S, Figini M . (2002). Re: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 94: 1031–1032 (author reply 1032).
Cardinale A, Lener M, Messina S, Cattaneo A, Biocca S . (1998). The mode of action of Y13-259 scFv fragment intracellularly expressed in mammalian cells. FEBS Lett 439: 197–202.
Chada S, Mhashilkar AM, Liu Y, Nishikawa T, Bocangel D, Zheng M et al. (2005b). Mda-7 gene transfer sensitizes breast carcinoma cells to chemotherapy, biologic therapies and radiotherapy: correlation with expression of bcl-2 family members. Cancer Gene Ther 13: 490–502.
Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D et al. (2004a). Bystander activity of Ad-mda7: human MDA-7 protein kills melanoma cells via an IL-20 receptor-dependent but STAT3-independent mechanism. Mol Ther 10: 1085–1095.
Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW et al. (2004b). MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol 4: 649–667.
Cochet O, Kenigsberg M, Delumeau I, Virone-Oddos A, Multon MC, Fridman WH et al. (1998). Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res 58: 1170–1176.
Cunningham CC, Chada S, Merritt JA, Tong A, Senzer N, Zhang Y et al. (2005). Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol Ther 11: 149–159.
Fearon ER, Vogelstein B . (1990). A genetic model for colorectal tumorigenesis. Cell 61: 759–767.
Fernandez-Sarabia MJ, Bischoff JR . (1993). Bcl-2 associates with the ras-related protein R-ras p23. Nature 366: 274–275.
Fisher PB . (2005). Is mda-7/IL-24 a ‘magic bullet’ for cancer? Cancer Res 65: 10128–10138.
Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR et al. (2003). Mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2: S23–S37.
Gupta P, Su ZZ, Lebedeva IV, Sarkar D, Sauane M, Emdad L et al. (2006). Mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (in press).
Hague A, Moorghen M, Hicks D, Chapman M, Paraskeva C . (1994). BCL-2 expression in human colorectal adenomas and carcinomas. Oncogene 9: 3367–3370.
Holmes M, Rosenberg E, Valerie K . (2003). Adenovirus expressing p53. Methods Mol Biol 234: 1–16.
Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 813–822.
Jiang H, Lin JJ, Su ZZ, Goldstein NI, Fisher PB . (1995). Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477–2486.
Kinoshita T, Yokota T, Arai K, Miyajima A . (1995). Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene 10: 2207–2212.
Kita K, Saito S, Morioka CY, Watanabe A . (1999). Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 80: 553–558.
Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K et al. (1996a). Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148: 1567–1576.
Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC . (1996b). Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422–2427.
Krajewski S, Thor AD, Edgerton SM, Moore II DH, Krajewska M, Reed JC . (1997). Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 3: 199–208.
Lebedeva IV, Sarkar D, Su ZZ, Gopalkrishnan RV, Athar M, Randolph A et al. (2006). Molecular target-based therapy of pancreatic cancer. Cancer Res 66: 2403–2413.
Lebedeva IV, Sarkar D, Su ZZ, Kitada S, Dent P, Stein CA et al. (2003). Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24. Oncogene 22: 8758–8773.
Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Gupta P et al. (2005a). Mda-7/IL-24: exploiting cancer's Achilles' heel. Mol Ther 11: 4–18.
Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB . (2002). The cancer growth suppressing gene mda-7 induces apoptosis selectively in human melanoma cells. Oncogene 21: 708–718.
Lebedeva IV, Su ZZ, Sarkar D, Gopalkrishnan RV, Waxman S, Yacoub A et al. (2005b). Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 24: 585–596.
Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA . (1991). Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51: 1744–1748.
Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, Mhashilkar AM et al. (2005). Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther 4: 291–304.
Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K et al. (2003). Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 63: 5105–5113.
Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR et al. (1999). Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res 59: 5239–5244.
Russo P, Malacarne D, Falugi C, Trombino S, O'Connor PM . (2002). RPR-115135, a farnesyltransferase inhibitor, increases 5-FU-cytotoxicity in ten human colon cancer cell lines: role of p53. Int J Cancer 100: 266–275.
Sarkar D, Dent P, Fisher PB . (2006). Melanoma differentiation associated gene-7 (mda-7)/interleukin-24 (IL-24), mda-7/IL-24: current perspectives on a unique member of the IL-10 family of cytokines. Anti-inflammatory Anti-allergy Agents Med Chem (in press).
Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB . (2005a). Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 102: 14034–14039.
Sarkar D, Su ZZ, Vozhilla N, Park ES, Randolph A, Valerie K et al. (2005b). Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice. Cancer Res 65: 9056–9063.
Shirasawa S, Furuse M, Yokoyama N, Sasazuki T . (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85–88.
Sklar MD . (1988a). The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239: 645–647.
Sklar MD . (1988b). Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48: 793–797.
Su Z, Emdad L, Sauane M, Lebedeva IV, Sarkar D, Gupta P et al. (2005). Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells. Oncogene 24: 7552–7566.
Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC et al. (2001). A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 98: 10332–10337.
Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S et al. (2006). Ionizing radiation enhances therapeutic activity of mda-7/IL-24: overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-x(L) or bcl-2. Oncogene 25: 2339–2348.
Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C et al. (2003). Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 22: 1164–1180.
Su ZZ, Madireddi MT, Lin JJ, Young CS, Kitada S, Reed JC et al. (1998). The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc Natl Acad Sci USA 95: 14400–14405.
Su ZZ, Shi Y, Fisher PB . (1997). Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene. Proc Natl Acad Sci USA 94: 9125–9130.
Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N et al. (2005). Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol Ther 11: 160–172.
Viale PH, Fung A, Zitella L . (2005). Advanced colorectal cancer: current treatment and nursing management with economic considerations. Clin J Oncol Nurs 9: 541–552.
Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M et al. (1988). Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525–532.
Ward RL, Todd AV, Santiago F, O'Connor T, Hawkins NJ . (1997). Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis. Cancer 79: 1106–1113.
Weinstein IB . (2002). Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 297: 63–64.
Yacoub A, Mitchell C, Hong Y, Schroeder M, Gopalkrishnan RV, Su Z-Z et al. (2004). MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 3: 739–751.
Yacoub A, Mitchell C, Lebedeva IV, Sarkar D, Su ZZ, McKinstry R et al. (2003a). mda-7 (IL-24) inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling. Cancer Biol Ther 2: 347–353.
Yacoub A, Mitchell C, Lister A, Lebedeva IV, Sarkar D, Su ZZ et al. (2003b). Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo. Clin Cancer Res 9: 3272–3281.
Young IT . (1977). Proof without prejudice: use of the Kolmogorov–Smirnov test for the analysis of histograms from flow systems and other sources. J Histochem Cytochem 25: 935–941.
Zhao L, Gu J, Dong A, Zhang Y, Zhong L, He L et al. (2005). Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer. Hum Gene Ther 16: 845–858.
Acknowledgements
The present study was supported in part by NIH Grants R01 CA097318 and R01 CA098712, the Samuel Waxman Cancer Research Foundation, the Chernow Endowment and a sponsored research award from Introgen Therapeutics Inc. PBF is the Michael and Stella Chernow Urological Cancer Research Scientist and a SWCRF Investigator.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lebedeva, I., Su, ZZ., Emdad, L. et al. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene 26, 733–744 (2007). https://doi.org/10.1038/sj.onc.1209813
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1209813
Keywords
This article is cited by
-
KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines
Scientific Reports (2015)
-
BI-69A11 enhances susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt
British Journal of Cancer (2014)
-
Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling
Oncogene (2008)